CPC A61K 31/728 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0048 (2013.01); A61K 38/08 (2013.01); A61K 38/10 (2013.01); A61K 47/60 (2017.08); A61K 47/6957 (2017.08); A61L 27/20 (2013.01); A61L 27/227 (2013.01); A61L 2400/10 (2013.01); A61L 2400/18 (2013.01); A61L 2430/06 (2013.01); A61L 2430/16 (2013.01)] | 8 Claims |
1. A method for treating dry eye in a subject comprising administering to the eye of a subject in need thereof, an effective amount of the biomaterial composition a biomaterial comprising at least one biologically compatible polymer having one or more hyaluronic acid (HA) binding peptides (HABPep) selected from the group consisting of: i) RRDDGAHWQFNALTVR (SEQ ID NO: 1) or a conservative amino acid substitution thereof at a residue position other than 4, 5, 6, 9, 10 or 11, ii) CRRDDGAHWQFNALTVR (SEQ ID NO: 2) or a conservative amino acid substitution thereof at a residue position other than 4, 5, 6, 9, 10 or 11, iii) GAAWQFNALTVR (SEQ ID NO: 9) or a conservative amino acid substitution thereof at a residue position other than 4, 5, 6, 9, 10 or 11, iv) GAHWQFAALTVR (SEQ ID NO: 10) or a conservative amino acid substitution thereof at a residue position other than 4, 5, 6, 9, 10 or 11, and v) GAHWQFNALTVA (SEQ ID NO: 11) or a conservative amino acid substitution thereof at a residue position other than 4, 5, 6, 9, 10 or 11, covalently linked to the biologically compatible polymer, and one or more extracellular matrix binding peptides (ECMBPep) covalently linked to the biologically compatible polymer.
|